Advanced Search

Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2014 December;105(6) > Minerva Medica 2014 December;105(6):515-27

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA MEDICA

A Journal on Internal Medicine

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236

Frequency: Bi-Monthly

ISSN 0026-4806

Online ISSN 1827-1669

 

Minerva Medica 2014 December;105(6):515-27

    CASE REPORTS

Topical pharmacologic approach with 5% lidocaine medicated plaster in the treatment of localized neuropathic pain

Provinciali L. 1, Lattanzi S. 1, Chiarlone R. 2, Fogliardi A. 3, Intelligente F. 4, Irace C. 5, Lanzilotta M. 6, Palomba R. 7, Storelli E. 8, Zampi M. 9

1 Clinica Neurologica, Dipartimento di Medicina Sperimentale e Clinica, Università Politecnica delle Marche, Ancona, Italia;
2 S.S. di Brachiterapia presso S.C. di Radioterapia Ospedale S. Paolo, Savona, Italia;
3 Unità Operativa di terapia del dolore e cure palliative, ASUR Marche, Area vasta N. 1, Ancona, Italia;
4 Chroinc Pain Service Anestesia Day-Surgery, IRCCS Humanitas Research Hospital;
5 Unità Operativa di Neurochirurgia, Casa di Cura IGEA, Milano, Italia;
6 Ambulatorio terapia dolore, Ospedale di Circolo Busto Arsizio, Varese, Italia;
7 Università degli Studi di Napoli “Federico II” Dipartimento di Neuroscienze, Cattedra di Anestesia e Rianimazione, Napoli, Italia;
8 SSvD Algologia, Ospedale Maggiore della Carità di Novara, Novara, Italia;
9 Università degli Studi di Napoli Federico II, Dipartimento di Neuroscienze e Scienze Riproduttive e Odontostomatologiche, Cattedra di Anestesia e Rianimazione Napoli, Italia

The treatment of neuropathic pain is a medical challenge. The responsiveness to the different classes of drugs is often unsatisfactory and frequently associated to a wide range of side effects. International guidelines suggest for the “localized” neuropathic pain the topical treatment with 5% lidocaine medicated plaster, alone or associated to systemic drugs, as the first choice since its favorable efficacy and tolerability profile. Many clinical experiences support the rationale for using 5% lidocaine medicated plaster in different kinds of localized neuropathic pain, such as postherpetic and trigeminal neuralgia, compressive syndromes, painful diabetic polyneuropathy and pain secondary to trauma or surgical interventions. This paper reports a series of clinical cases whose heterogeneity suggests the wide burden of applicability of the topical 5% lidocaine, either alone and associated to systemic drugs. All the described conditions were characterized by a highly intense pain, not adequately controlled by actual medications, which improved after the use of topical lidocaine. The good response to lidocaine allowed the reduction, of even the withdrawal, of concurrent drugs and improved the patients’ quality of life.

language: Italian


FULL TEXT  REPRINTS

top of page